Genmab — Februar 2017
-
God mirgen
-
Ifht at det er md 2 i 2 linie, synes jeg ikke at det er prangende
-
Jeg er godt nok bange for at vi ikke har set kurs 1100 for sidste gang. Men man skal da aldrig sige aldrig
-
Jeg ville i hvert fald ikke selv give 1400+ for en aktie i dag men den udvikling i salget jeg har set de sidste 2 mdr
-
Enig StockBull
-
Interessant at Børsen var først ude med salgstal. De har nok købt sig adgang til Symphony Healths database nu. Så behøver vi ikke vente på analytikere fremover.
-
Stockbull jo jo. Men nuværende kurs afspejler jo også forventninger på et helt andet niveau end 1,5 mia USD
-
Uanset uenighederne så vil jeg følge AB's handelsmønster i dag. Så må det vise sig om det bliver køb eller sælg
god dag -
Fra Novod "We note that January had two fewer sales/infusion days than December (20 versus 22 due to fewer weekdays as well as one additional holiday, with New Year's Day (2 January) and Martin Luther King (16 January)). Adjusting for the difference in business days (making it comparable to December's), Darzalex would have recorded USD 67m in January, corresponding to USD 3.05m per day versus USD 2.51m in December, ie up 21.5% m/m."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind